Robert W. Baird Lowers IQVIA (NYSE:IQV) Price Target to $223.00

IQVIA (NYSE:IQV) had its price objective cut by Robert W. Baird from $256.00 to $223.00 in a research note published on Friday, Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Several other research firms have also recently weighed in on IQV. Barclays decreased their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, Royal Bank of Canada began coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $261.56.

IQVIA Trading Up 0.5 %

IQVIA stock opened at $210.19 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a 50-day moving average of $233.55 and a 200-day moving average of $229.64. The company has a market cap of $38.15 billion, a price-to-earnings ratio of 27.58, a P/E/G ratio of 2.07 and a beta of 1.51. IQVIA has a one year low of $190.20 and a one year high of $261.73.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Foundation Advisors boosted its holdings in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Team Hewins LLC grew its stake in shares of IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after buying an additional 46 shares during the period. Invera Wealth Advisors LLC increased its holdings in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares in the last quarter. Covestor Ltd raised its holdings in IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after buying an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.